241 related articles for article (PubMed ID: 22595378)
1. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Romero J; Rebarber A; Saltzman DH; Schwartz R; Peress D; Fox NS
Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
[TBL] [Abstract][Full Text] [Related]
2. Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17-hydroxyprogesterone caproate.
Combs CA; Garite TJ; Maurel K; Das A;
Am J Perinatol; 2014 Dec; 31(12):1023-30. PubMed ID: 24566755
[TBL] [Abstract][Full Text] [Related]
3. The significance of a positive fetal fibronectin in the setting of a normal cervical length in twin pregnancies.
Fox NS; Rebarber A; Roman AS; Klauser CK; Saltzman DH
Am J Perinatol; 2012 Apr; 29(4):267-72. PubMed ID: 21818730
[TBL] [Abstract][Full Text] [Related]
4. Combined fetal fibronectin and cervical length and spontaneous preterm birth in asymptomatic triplet pregnancies.
Fox NS; Rebarber A; Roman AS; Klauser CK; Peress D; Saltzman DH
J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2308-11. PubMed ID: 22563765
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
[TBL] [Abstract][Full Text] [Related]
6. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
7. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery.
Kurtzman J; Chandiramani M; Briley A; Poston L; Das A; Shennan A
Am J Obstet Gynecol; 2009 Mar; 200(3):263.e1-6. PubMed ID: 19254585
[TBL] [Abstract][Full Text] [Related]
8. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery in triplet gestations.
Roman AS; Pessel C; Fox N; Klauser CK; Saltzman D; Rebarber A
J Matern Fetal Neonatal Med; 2012 Oct; 25(10):1921-3. PubMed ID: 22489752
[TBL] [Abstract][Full Text] [Related]
9. Fetal fibronectin, cervical length, and the risk of preterm birth in patients with an ultrasound or physical exam indicated cervical cerclage.
Kim RS; Gupta S; Lam-Rachlin J; Saltzman DH; Rebarber A; Fox NS
J Matern Fetal Neonatal Med; 2016 Nov; 29(22):3602-5. PubMed ID: 26782923
[TBL] [Abstract][Full Text] [Related]
10. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
11. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
12. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
13. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
15. The Independent Association of a Short Cervix, Positive Fetal Fibronectin, Amniotic Fluid Sludge, and Cervical Funneling with Spontaneous Preterm Birth in Twin Pregnancies.
Spiegelman J; Booker W; Gupta S; Lam-Rochlin J; Rebarber A; Saltzman DH; Monteagudo A; Fox NS
Am J Perinatol; 2016 Oct; 33(12):1159-64. PubMed ID: 27434692
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of fetal fibronectin in the prediction of pre-term birth in a low socio-economic setting hospital in Ecuador.
Díaz J; Chedraui P; Hidalgo L; Medina M
J Matern Fetal Neonatal Med; 2009 Feb; 22(2):89-93. PubMed ID: 19085632
[TBL] [Abstract][Full Text] [Related]
17. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co AL; Walker HC; Hade EM; Iams JD
Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
19. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
20. Gestational age at cervical length and fetal fibronectin assessment and the incidence of spontaneous preterm birth in twins.
Fox NS; Saltzman DH; Fishman A; Klauser CK; Gupta S; Rebarber A
J Ultrasound Med; 2015 Jun; 34(6):977-84. PubMed ID: 26014316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
